Loading...
PYC Therapeutics Limited
PYC.AX•ASX
Healthcare
Biotechnology
A$1.21
A$-0.03(-2.42%)
PYC Therapeutics Limited (PYC.AX) Financial Performance & Income Statement Overview
Review PYC Therapeutics Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
39.56%
↑ 39.56%
Operating Income Growth
0.78%
↑ 0.78%
Net Income Growth
-65.54%
↓ 65.54%
Operating Cash Flow Growth
-58.01%
↓ 58.009%
Operating Margin
-200.55%
↓ 200.55%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-192.90%
↓ 192.90%
ROE
-70.92%
↓ 70.92%
ROIC
-88.15%
↓ 88.15%
PYC Therapeutics Limited (PYC.AX) Income Statement & Financial Overview
Review PYC Therapeutics Limited's (PYC.AX) income statement with detailed quarterly and annual figures.
Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
---|---|---|---|---|
Revenue | $13.15M | $8.91M | $12.33M | $3.47M |
Cost of Revenue | $0.00 | $336421.00 | $93504.00 | $457714.00 |
Gross Profit | $13.15M | $8.57M | $12.24M | $3.01M |
Gross Profit Ratio | $1.00 | $0.96 | $0.99 | $0.87 |
R&D Expenses | $34.56M | $21.85M | $17.20M | $17.95M |
SG&A Expenses | $2.01M | $2.16M | $1.53M | $2.01M |
Operating Expenses | $36.57M | $24.006M | $18.73M | $19.96M |
Total Costs & Expenses | $36.57M | $24.34M | $18.82M | $20.42M |
Interest Income | $580673.00 | $215303.00 | $66191.00 | $15657.00 |
Interest Expense | $12550.00 | $36659.00 | $14933.00 | $12355.00 |
Depreciation & Amortization | $731342.00 | $336421.00 | $93504.00 | $457714.00 |
EBITDA | -$23.02M | -$15.10M | -$18.64M | -$16.49M |
EBITDA Ratio | -$1.75 | -$2.70 | -$1.52 | -$5.75 |
Operating Income | -$23.42M | -$24.34M | -$18.82M | -$20.42M |
Operating Income Ratio | -$1.78 | -$2.73 | -$1.53 | -$5.88 |
Other Income/Expenses (Net) | -$8.08M | $178644.00 | $71125.00 | $3303.00 |
Income Before Tax | -$31.51M | -$24.16M | -$18.75M | -$20.41M |
Income Before Tax Ratio | -$2.40 | -$2.71 | -$1.52 | -$5.88 |
Income Tax Expense | -$8.65M | -$8.91M | -$12.33M | -$3.47M |
Net Income | -$22.63M | -$15.09M | -$6.55M | -$16.24M |
Net Income Ratio | -$1.72 | -$1.69 | -$0.53 | -$4.68 |
EPS | -$0.005 | -$0.004 | -$0.002 | -$0.005 |
Diluted EPS | -$0.005 | -$0.004 | -$0.002 | -$0.005 |
Weighted Avg Shares Outstanding | $4.09B | $3.78B | $3.33B | $3.22B |
Weighted Avg Shares Outstanding (Diluted) | $4.10B | $3.78B | $3.33B | $3.22B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan